L

R&D Novel CAR Intern

Legend Biotech US · Somerset, New Jersey, United States

onsiteinternshipmid level

About this role

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma.

Legend Biotech is seeking a R&D Novel CAR Intern as part of the Research & Early Development team based in Somerset, NJ.

Role Overview

This position offers hands‑on experience in designing and developing novel CAR constructs or vectors for next‑generation cell therapies. The intern will perform molecular/cellular biology experiments, analyze data, and collaborate across teams to advance early‑stage therapeutic concepts.

Key Responsibilities

Assist in evaluating novel CAR constructs/vectors using molecular and cellular techniques.
Perform cell culture, transfection, and functional assays to assess CAR/vector performance.
Analyze experimental data, maintain accurate records, and present findings to the research team.
Collaborate cross‑functionally to progress early discovery programs.

Requirements

Basic knowledge of molecular biology, cell culture, and immunology principles.
Familiarity with flow cytometry, PCR, ELISA, or other immunoassays a plus.
Strong attention to detail, organizational skills, and ability to work in a fast‑paced environment.

Skills You’ll Gain

Exposure to cutting‑edge CAR‑T research.
Technical skills in functional testing (flow cytometry, PCR, ELISA) and scientific communication.
Mentorship and opportunities to contribute to impactful projects.

#Li-JR1

#Li-Contract

Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech.

EEO Statement

It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances.

Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company.

For information related to our privacy policy, please review: Legend Biotech Privacy Policy.

About Legend Biotech US

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of an immunotherapy in the treatment of multiple myeloma.